NHS Weight-Drug Rollout Stirs MP Outrage

Members of Parliament have expressed significant concern over the slow rollout of the weight-loss drug Mounjaro on the NHS. Their report indicates that only approximately six percent of eligible patients will receive the medication within the first three years of its introduction.

This limited availability on the NHS is compelling millions to source these treatments through private firms, leading to the development of a "two-tier system." MPs argue this system prioritizes those who can afford private care over clinical need, thus deepening existing health inequalities.

Pharmacy leaders echo these concerns, noting that the slow NHS rollout creates a "postcode lottery" and inadvertently fuels a black market for unlicensed GLP-1 treatments. They emphasize the need for a faster, more equitable distribution.

In response, an NHS spokesperson stated that the health service is actively testing new methods to accelerate access to these medicines, aiming to benefit millions more. The National Institute for Health and Care Excellence (Nice) recommended Mounjaro for overweight and obesity management in June 2024.

MPs also highlighted issues within specialized pediatric clinics for children with obesity, reporting long waiting times and insufficient capacity. The report calls for a national framework with ambitious targets for GLP-1 access and a review of regulatory bodies to combat illegal trade.